For protection against cancers, both boys and girls benefit from getting HPV vaccine
December 12, 2011 By Neville Golden and Sophia Yen in Cancer
On Oct. 25, the U.S. Centers for Disease Control and Prevention recommended that all adolescent boys be immunized against the human papilloma virus, which causes several types of cancer in both sexes. We strongly support this landmark decision, which builds on the CDCs 2006 recommendation to immunize all girls against HPV.
The vaccines, which protect against either two or four HPV strains, could prevent about 60 percent of mouth and throat cancers, 76 percent of cervical cancer, 87 percent of anal cancer, 31 percent of penile cancer and 44 to 56 percent of vulvar and vaginal cancers. Yet some parents are skeptical of vaccinations value in cancer prevention or reluctant to immunize their sons and daughters against a sexually transmitted disease.
HPV is the No. 1 STD in the United States. About 6 million Americans are infected each year. Up to 80 percent of adults are infected with this virus during their lifetimes, with half becoming infected within four years of sexual debut. If you have two sexual partners in your lifetime, you have a 70 percent chance of being infected with one of the four common strains covered by the HPV vaccines.
Fortunately, most peoples bodies get rid of HPV infection spontaneously. However, the oncogenic types of HPV, those that cause cancer, are more likely to persist.
To offer the best protection against cancer, the CDC and medical community recommend that the HPV vaccine be given at age 11 to 12, before the onset of sexual activity. According to the 2009 national Youth Risk Behavior Survey, more than one out of every 20 high school students reported they had sex before the age of 13, and 32 percent of high school ninth-graders reported they had had sexual intercourse.
The HPV vaccine is a safe and extremely effective vaccine against certain types of HPV, especially the types most likely to cause cancer. More than 35 million doses of the vaccine have been given in the United States. The only major confirmed side effect after continuous surveillance is pain and some risk of fainting within 15-30 minutes after injection.
Two vaccines are available the quadrivalent one protects against four types of HPV virus (6,11, 16 and 18) and the other protects against two types (16 and 18). Both protect against types 16 and 18, the cancer-causing types of the virus. The quadrivalent vaccine is the only vaccine currently licensed for use in the United States for boys, but either vaccine can be used in girls. There are approximately 160 types of HPV virus.
As adolescent medicine specialists, we want parents who are struggling with the decision to vaccinate their sons and daughters to understand that the vaccine is very low-risk and the protection it confers against several life-threatening cancers is substantial. Parents who are reluctant to think about their childrens future sexual behavior should consider that even young people who are sexually abstinent until marriage are still vulnerable to infection after marriage from a spouse who had been previously infected. In addition, as adolescent medicine physicians, we often see young patients who have become sexually active without their parents knowledge.
The HPV vaccine is the first vaccine that has the potential to prevent more than one type of cancer. We strongly support protecting both boys and girls against these cancers by immunizing them before they become sexually active.
Provided by
Stanford University Medical Center
-
Study: Males should be given HPV vaccine
Nov 28, 2007 |
not rated yet |
0
-
US patent awarded for Rochester's pioneering HPV vaccine work
Nov 22, 2011 |
not rated yet |
0
-
Lack of clarity about HPV vaccine and the need for cervical cancer screening
Jul 07, 2011 |
not rated yet |
0
-
New HPV vaccine under study
Nov 19, 2007 |
not rated yet |
0
-
Cervical vaccine also protects against anal cancer risk
Aug 23, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
New smartphone application improves colonoscopy preparation
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer
22 hours ago |
not rated yet |
0
Research examines new methods for managing digestive health
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
Cancer
22 hours ago |
not rated yet |
1
New colonoscope provides ground-breaking view of colon
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
Cancer
May 18, 2013 |
5 / 5 (2) |
0
ASCO: combo antibody therapy effective for melanoma
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer
May 17, 2013 |
not rated yet |
0
Risk factors ID'd for poor cutaneous cell CA outcomes
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer
May 17, 2013 |
not rated yet |
0
|
Researchers identify a potential new risk for sleep apnea: Asthma
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
New theory on genesis of osteoarthritis comes with successful therapy in mice
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
Computational tool translates complex data into simplified 2-dimensional images
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
Study finds that sleep apnea and Alzheimer's are linked
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
Ginger compounds may be effective in treating asthma symptoms
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
Dec 12, 2011
Rank: 1 / 5 (1)
Hundreds of girls who received the vaccines have had serious neurological problems and scores died shortly after being vaccinated.
There is NO justification for such a recommendation. Safety is bad and efficacy of the vaccine in *actually* preventing any cancers has not been proven. What has been observed are antibodies against an essentially benign virus. Where is the cancer connection?